Treatment Protocol for Endometrial Intraepithelial Neoplasia in Premenopausal Women
For premenopausal women with endometrial intraepithelial neoplasia (EIN), hysterectomy with bilateral salpingo-oophorectomy remains the definitive standard treatment, but fertility-sparing progestin therapy can be offered to highly selected patients who meet strict criteria and accept close surveillance. 1
Initial Workup Requirements
Before considering any treatment approach, the following diagnostic steps are mandatory:
- Dilatation and curettage (D&C) is required—not pipelle biopsy—as D&C is superior for accurate tumor grading 1
- Expert gynecologic pathologist review must confirm the EIN diagnosis 1, 2, 1
- Pelvic MRI to exclude myometrial invasion, adnexal involvement, or pelvic node metastases 1
- Referral to specialized centers for fertility-sparing management 1
Standard Definitive Treatment
Total hysterectomy with bilateral salpingo-oophorectomy is the gold standard because:
- Up to 50% of EIN cases harbor concurrent endometrial carcinoma on final pathology 3, 4, 5
- This provides definitive cure with 5-year survival of 93% 1
- It eliminates the 30-40% recurrence risk associated with conservative management 1
Fertility-Sparing Protocol (Non-Standard Approach)
Patient Selection Criteria
Fertility-sparing therapy may be considered ONLY if ALL of the following are met:
- Confirmed EIN (or grade 1 endometrioid adenocarcinoma) by expert pathologist 1, 2, 1
- No myometrial invasion on MRI 1
- No extrauterine disease 1, 2
- Patient desires future fertility 1, 3
- Patient accepts this is non-standard treatment 1, 2
- Patient willing to undergo intensive surveillance 1, 2
- Patient understands eventual hysterectomy will be needed 1
Medical Treatment Options
First-line progestin therapy (choose one):
- Medroxyprogesterone acetate (MPA): 400-600 mg/day orally 1, 3, 2
- Megestrol acetate (MA): 160-320 mg/day orally 1, 3, 2
- Levonorgestrel-releasing intrauterine device (LNG-IUD): Can be used alone or with GnRH analogues 1, 2
The LNG-IUD demonstrates similar remission and recurrence rates as oral progestins, with some evidence suggesting higher regression rates compared to oral therapy alone 1, 4. Continuous progestin therapy is superior to cyclic regimens 4.
Surveillance Protocol
Intensive monitoring is mandatory:
- Endometrial sampling every 3-6 months via biopsy or D&C 1, 3, 6, 4
- Response assessment at 6 months with D&C and imaging 1
- Clinical re-evaluation every 6 months for patients not undergoing hysterectomy 1
Treatment Response Management
At 6-month assessment:
Complete response: Encourage immediate conception and refer to fertility clinic 1
Partial response with desire to delay pregnancy: Consider maintenance progestin therapy for additional 6 months 1
No response or persistent disease after 6 months: Proceed to standard hysterectomy 1, 3, 6
Disease progression at any time: Immediate hysterectomy 1, 3
Post-Treatment Hysterectomy
Hysterectomy with bilateral salpingo-oophorectomy is recommended:
- After completion of childbearing 1, 2
- After age of potential pregnancy 1
- Following disease recurrence (30-40% risk) 1
- If no response after 6-12 months of therapy 3, 6
Ovarian preservation may be considered in selected cases based on age and genetic risk factors, but bilateral salpingectomy is recommended if ovaries are preserved 1, 7.
Critical Caveats
Contraindications to progestin therapy include:
- Breast cancer
- Stroke or myocardial infarction history
- Pulmonary embolism or deep vein thrombosis
- Active smoking 3, 6
Do not rely on progesterone receptor status for treatment decisions—50% of PgR-negative patients still respond to progestin therapy 1.
High recurrence risk: Even after achieving complete response, 35% of patients experience recurrence, emphasizing the importance of eventual definitive surgery 3, 6.
The evidence consistently demonstrates that while fertility-sparing treatment can achieve temporary disease control in carefully selected patients, hysterectomy remains the only curative approach with elimination of recurrence risk. The decision to pursue conservative management must balance the patient's reproductive goals against the substantial risks of disease persistence, progression, and recurrence.